Pfizer to Acquire Metsera, Expand Obesity and Cardiometabolic Drug Pipeline
Pfizer is set to acquire Metsera, a clinical-stage biopharmaceutical company focused on developing the next generation of medicines for obesity and cardiometabolic diseases.
MET-097i | 23/09/2025 | By Dineshwori | 102
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy